Monitoring Living Donor Liver Functions by Thromboelastometry

Monitoring Post-transplant Living Donor Liver Functions by Thromboelastometry. A Prospective Observational Study.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02336191

Acronym

TGF

Enrollment

Registered

2015-01-12

Start date

2014-06-30

Completion date

2015-08-31

Last updated

2017-03-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

THROMBELASTOGRAPHY and Liver Graft Functions

Keywords

living donor liver transplantation, graft function, thromboelastometry

Brief summary

A prospective Observational study including 50 living donor liver transplant recipients to monitor the graft functions through thromboelastometry

Detailed description

This is a prospective observational study Includes 50 living donor liver transplant recipients performed in gastroenterology surgical center - Mansoura University liver transplantation program. Study period: from June 2014 to May 2015 The early post-operative graft functions will be correlated with concomitant monitored thromboelastometric (TEM) parameters derived from a ROTEM Delt device TEM Samples will be collected at the following times: Pre-transplant 10 minutes post portal declamping at ICU admission Morning of Days from 1 to 7 Laboratory data relevant to graft functional status will be collected at the same times.

Interventions

PROCEDUREliving donor liver transplantation

living donor liver transplantation

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Inclusion criteria

* Living donor liver transplant recipients successively performed in the liver transplantation program - Mansoura university

Exclusion criteria

* Non

Design outcomes

Primary

Measure	Time frame	Description
r (correlation coefficient) between clot firmness time at 20 minutes, clotting time and INR	20 minutes after starting the TEG test	Both blood sample for INR and other lab test and the sample for TEG will be simultaneously drawn from the arterial line for reading of days 0,1 and 2 then from the CVP for the rest of the study readings

Secondary

Measure	Time frame
r (correlation coefficient) between clotting time , clot firmness time at 20 minutes and serum bilirubin	20 minutes after the start of the TEG test
r (correlation coefficient) between clotting time , clot firmness time at 20 minutes and serum SGPT	20 minutes after the start of the TEG test

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026